Impax Laboratories Inc

Impax Laboratories — J.P. Morgan Healthcare Conference 2013

18 slides from Impax Laboratories's conference presentation, Jan 8, 2013

  1. Slide 1: J.P. Morgan Healthcare Conference

    Slide 1: J.P. Morgan Healthcare Conference

    D IMPAX” J.P. Morgan Healthcare Conference iaitrocurnes January 7, 2013 IPXL NASDAq LISTED

  2. Slide 2: Safe Harbor Statement

    Slide 2: Safe Harbor Statement

    Safe Harbor Statement “Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: To the extent any statements made in this presentation contain information that is not historical, these statements are forward-looking in nature and express the beliefs and expectations of mana

  3. Slide 3: Well-Positioned for Future Growth

    Slide 3: Well-Positioned for Future Growth

    Well-Positioned for Future Growth Investment Considerations Targeting Sustainable Generic pipeline targeting $26B U.S. sales Generic and Brand pipeline focused on Central Nervous System (CNS) Specialized Solid platform on which to build long-term growth Brand Markets Established Track record of comp

  4. Slide 4: Two Platforms for Growth

    Slide 4: Two Platforms for Growth

    Two Platforms for Growth BS GLopa @ IMPAX PHARMACEUTICALS PHARMACEUTICALS: Generic Platform Branded Platform Unique targeted ANDAs Solid Oral Dosage (SOD) Alternative Dosage Form (ADF) First-to-File/First-to-Market emphasis Focusing on sustainable products Partnerships/M&A primarily on ADFs 75 produ

  5. Slide 5: Strategy to Create Long Term Growth

    Slide 5: Strategy to Create Long Term Growth

    Strategy to Create Long Term Growth Revenue Growth Operational Opportunities Improvements Diversifying Generic Right-sizing manufacturing Business product mix costs and capacity Focusing on building a Driving global quality and strong Brand pipeline compliance Executing business development and M&A

  6. Slide 6: Strategic Initiatives for Generic Growth

    Slide 6: Strategic Initiatives for Generic Growth

    Strategic Initiatives for Generic Growth GLOBAL PHARMACEUTICALS [ | 1 Srgantc; Growin Strategic Partnershi Strategic M &A Alternative Dosage y . Y in ADFs in ADFs Forms (ADF)

  7. Slide 7: Diversifying Currently Marketed Portfolio

    Slide 7: Diversifying Currently Marketed Portfolio

    Diversifying Currently Marketed Portfolio 48 Currently Marketed Products Alternative Controlled-Release Dosage Form 14 Solid Oral 19% 29% Other Solid Oral 52% Note: Data as of January 7, 2013. Percentages reflect individual share of the number of products in currently marketed portfolio. (J) JMPAX

  8. Slide 8: Growing Alternative Dosage Form Portfolio

    Slide 8: Growing Alternative Dosage Form Portfolio

    Growing Alternative Dosage Form Portfolio ADF Products Offer Potential Market Sustainability 24 Future Opportunities are ADFs A number of them still FTF/FTM opportunities $5B Current U.S. Brand/Generic Sales 33 = Currently Marketed Pending at FDA mw Under Development 2008 2009 2010 2011 2012 Cumulat

  9. Slide 9: Diversifying Generic Product Pipeline

    Slide 9: Diversifying Generic Product Pipeline

    Diversifying Generic Product Pipeline 75 Future Opportunities Pending at FDA or Under Development $26B Current U.S. Brand/Generic Sales 44 31 6 J 22 18 | 11 Pending at FDA Under Development m Other Solid Oral Controlled-Release Solid Oral Alternative Dosage Form 18 Total Other SO 33 Total C-R SO 24

  10. Slide 10: Numerous Potential Near-Term Opportunities

    Slide 10: Numerous Potential Near-Term Opportunities

    Numerous Potential Near-Term Opportunities Generic Pipeline Designed to Drive Future Growth A Highlight of Some of the Near-Term Potential Generic Launches gConcerta® gTrilipix® gWelchol® tablets (FTF) $1.2B brand & generic sales $551M brand sales 3 months exclusivity expected gSolaraze® Gel (FTF) g

  11. Slide 11: Strategic Initiatives for Brand Growth

    Slide 11: Strategic Initiatives for Brand Growth

    Strategic Initiatives for Brand Growth CD LUPAX ii [ | ] Organic Growth Partnerships Me Ss Neurology & Primarily in Neurology & Ree ATV Neurology Area Psychiatry Areas eyOnieNy es (Products/Companies) "1

  12. Slide 12: Building a Brand Product Pipeline

    Slide 12: Building a Brand Product Pipeline

    Building a Brand Product Pipeline PROJECT [Gu sielaazess PHASE II PHASE Ill REGISTRATI APPROVED Zomig® Migraine Rytary™ Parkinson's Disease (carbidopa-levodopa) IPX159 Restless Legs Syndrome- In Phase Ilb study, topline results expected in 1Q13 _ IPX218 Epilepsy Parkinson's Disease IPX203. 8 Parkins

  13. Slide 13: Continuing Our Commercial Success

    Slide 13: Continuing Our Commercial Success

    Continuing Our Commercial Success Building relationships with neurologists since July 2006 = Licensed exclusive U.S. commercialization rights to Zomig® = Began commercializing Zomig® in April 2012 = Increased NRx sales since April 2012 8 ' Impax Pharmaceuticals 8% g i) 9 §7 | 67% 68% 67% 6.7% 9% 6.7

  14. Slide 14: RYTARY (IPX066): Preparing for Launch

    Slide 14: RYTARY (IPX066): Preparing for Launch

    RYTARY™ (IPX066): Preparing for Launch Carbidopa and Levodopa Extended-release Capsule PATENT DEc. FEB. JAN. INFORMATION 2011 2012 201 THROUGHOUT 2012/1Q13 Rytary™ (IPX066) for the Symptomatic Treatment of Parkinson’s Disease Pre-launch planning 1st Patent Granted Building sales & Aug. 2006 FDA mark

  15. Slide 15: Investments Drove Revenue Growth

    Slide 15: Investments Drove Revenue Growth

    Investments Drove Revenue Growth ated Significant Resources to Fund Business Development and M&A Financial Flexibility + in cash/cash equivalents and NO DEBT $513 $358 i! | 2004 2005 2006 2007 2008 2009 2010 2011 $ millions Note: $340M+ cash and cash equivalents as of September 30, 2012. Annual reve

  16. Slide 16: 2013 Objectives

    Slide 16: 2013 Objectives

    16 2013 Objectives Resolve Warning Letter (WL) in Hayward Potential 2013 generic product launches, including: * gConcerta® and many undisclosed pending ANDAs (all requiring resolution of WL) * gSolaraze® Gel (Tolmar partnership — resolution of WL not required) RYTARY™ approved and launched » PDUFA d

  17. Slide 17: 2013 Financial Forecast

    Slide 17: 2013 Financial Forecast

    7 2013 Financial Forecast Gross margin 2013 Forecast ($ in millions) Low to mid 50% range Total R&D $101 - $109 Generic R&D (includes patent litigation) $63 - $67 Brand R&D $38 - $42 SG&A $154 - $162 Amortization expense) Approximately $14 Tax rate 34% - 36% Note: As of January 7, 2013. Contains for

  18. Slide 18: Well-Positioned for Future Growth

    Slide 18: Well-Positioned for Future Growth

    Well-Positioned for Future Growth Investment Considerations Targeting Sustainable Generic pipeline targeting $26B U.S. sales Generic and Brand pipeline focused on Central Nervous System (CNS) Specialized Solid platform on which to build long-term growth Brand Markets Established Track record of comp

Source: SEC EDGAR · 8-K filed Jan 8, 2013

More decks from Impax Laboratories Inc